Fig. 4From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemiaEffect of ADA on inotuzumab ozogamicin clearance in patients with relapsed or refractory ALL. ADA = anti-drug antibody; ALL = acute lymphoblastic leukemiaBack to article page